IBM joins NIH effort to diagnose schizophrenia using AI

IBM today announced that, in collaboration with researchers from Harvard Medical School, Mount Sinai School of Medicine, Stanford University, and the Northern California Institute for Research and Education, it will undertake a new initiative funded by the U.S. National Institutes of Health to investigate whether AI can be used to better identify people at risk of developing schizophrenia. It’s a part of the multimillion-dollar, multiyear Accelerating Medicines Partnership (AMP) program, a collaboration between the National Institute of Health (NIH), the U.S. Food and Drug Administration (FDA), pharmaceutical companies, biotech firms, and nonprofit organizations to develop new diagnostics and therapies for patients.

Read More